Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

Is Gilead Sciences Stock Underperforming the Nasdaq?

With a market cap of $80.6 billion, Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company specializing in drugs for HIV, liver diseases, hematology/oncology, and inflammation/respiratory diseases. Headquartered in California, its HIV franchise includes key therapies like Genvoya, Odefsey, Descovy, Biktarvy, and Truvada. The company also offers hepatitis C virus drugs like Harvoni and Epclusa and an HBV drug. 

Companies valued at $10 billion or more are generally considered “large-cap” stocks, and Gilead Sciences fits this criterion perfectly. The pharma company boasts a robust portfolio of innovative antiviral and antiretroviral therapies, led by its flagship drug, Truvada, and is expanding into oncology through strategic collaborations and acquisitions. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.